Positive PIVOT-PO phase III data show tebipenem HBr’s potential as the first oral carbapenem antibio - TheNote.app

GSK press releases

Follow

Positive PIVOT-PO phase III data show tebipenem HBr’s potential as the first oral carbapenem antibiotic for patients with complicated urinary tract infections (cUTIs)

Data presented at IDWeek 2025 after study stopped early for efficacy

https://www.gsk.com/en-gb/media/press-releases/positive-pivot-po-phase-iii-data-show-tebipenem-hbr-s-potential-as-the-first-oral-carbapenem-antibiotic-for-patients-with-complicated-urinary-tract-infections-cutis/ gsk.com

RSS Hunter • Oct 21, 2025